Related Experiment Video
Updated: Mar 2, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Acellular pertussis vaccine efficacy: An updated systematic review and meta -analysis
Roxana Mansour-Ghanaei1, Maziar Moradi-Lakeh2, Sareh Shakerian3
1MD, Pediatric Infectious Specialist, Pediatric Infections Research Center, Mofid children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. roxanaghanaie@yahoo.com.
Insights
The acellular pertussis vaccine demonstrates superior efficacy and safety compared to the whole cell vaccine in children. It also shows acceptable effectiveness in high-risk adults, supporting its introduction into national immunization programs.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Rising incidence of pertussis (whooping cough) globally necessitates updated vaccination strategies.
- Current Expanded Program on Immunization (EPI) in Iran uses whole cell pertussis vaccines.
- Need to evaluate acellular pertussis vaccines for children and high-risk adults.
Purpose of the Study:
- To systematically review and meta-analyze the efficacy of acellular pertussis vaccines in children and high-risk adults.
- To compare the effectiveness of acellular vaccines against whole cell vaccines and placebo.
- To provide evidence for the potential introduction of acellular vaccines into Iran's national immunization program.
Main Methods:
- Systematic literature review focusing on previously published systematic reviews.
- Methodological quality assessment using the AMSTAR tool.
- Updated evidence search until February 2014, followed by meta-analysis using Stata.
Main Results:
- Acellular vs. whole cell vaccine efficacy in children: pooled estimate 0.68 (95% CI, 0.55-0.81).
- Acellular vs. placebo efficacy in children: pooled estimate 0.70 (95% CI, 0.60-0.80).
- Acellular booster dose efficacy vs. placebo: pooled estimate 0.87 (95% CI, 0.85-0.88).
- Acellular vaccine efficacy in high-risk adults: pooled estimate 0.78 (95% CI, 0.64-0.93).
Conclusions:
- Acellular pertussis vaccines exhibit superior performance and safety over whole cell vaccines in children.
- The acellular vaccine demonstrates acceptable efficacy for high-risk adult populations.
- Evidence supports the integration of acellular pertussis vaccines into national immunization schedules.
Abstract:
Background: Recent studies indicate an increased incidence of pertussis disease in recent years. The aim of this study was to evaluate the efficacy of the acellular vaccine for children (as a replacement of current whole cell vaccine in the Expanded Program on Immunization) and for high-risk adults in Iran through updating current best available evidence. Methods: We performed a systematic literature review in relevant databases we focused on previously published systematic reviews to select those that address our questions. The AMSTAR (assessing the methodological quality of systematic reviews) tool was used for screening available reviews. Then search in databases was done until Feb 2014 to update the evidence. We pooled results using meta-analysis methods by Stata statistical package. Results: Eleven systematic review articles were included in the initial evaluation. In the end, two systematic reviews on acellular vaccine booster doses and the acellular vaccine in children were selected as the baseline evidence. In the update phase, new clinical trials were screened, and the results were updated. Overall pooled estimate of relative efficacy of acellular to whole cell was 0.68 (95% CI, 0.55-0.81) for children immunization Pooled estimates for the efficacy of acellular versus placebo were 0.70 (95% CI, 0.60-0.80). Overall pooled estimate of efficacy of booster dose of acellular was 0.87(95% CI, 0.85-0.88) compared to placebo. In addition pooled estimate of acellular vaccine efficacy based on response to antigen was 0.78(95% CI, 0.64-0.93) in highrisk group. Conclusion: The results show higher performance and safety of the acellular vaccine in the prevention of pertussis in children versus the whole cell vaccine. Moreover, the efficacy of the acellular vaccine in high-risk adult groups is acceptable. This study provides evidence in favor of the introduction of an acellular vaccine to the national program of immunization. Studies on cost effectiveness and aspects of policy analysis are recommended.
More Related Videos
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020